Latest Period
Q2 2026
Security Snapshot
Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (TOI) Institutional Ownership
CUSIP: 68236X100
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
119
Shares (Excl. Options)
40,090,586
Price
$5.43
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- TOI
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 40,090,586
- Total 13F value
- $217,590,724
- Portfolio coverage rank
- 0%
- Share change
- +1,374,754
- Value change
- +$22,311,550
- Number of holders
- 119
- Shares outstanding
- 101,268,340
- SEC-reported price per share
- $5.29
- Insider filing price
- $5.29
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TOI - Starling Oncology, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 68236X100.
- 119 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 115 to 119 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $118,924,902 to $217,590,724.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 119 institutions filings for Q2 2026.
Security key
68236X100
Latest holder period
Q2 2026
13F holders
119
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
TOI full holder history
Oncology Institute, Inc. SEC filings
Oncology Institute, Inc. company facts
Oncology Institute, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68236X100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
TOI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Chernett Jorey | 10% | $27,110,730 | 10,115,944 | Chernett Jorey | 13 Mar 2026 | |||
| M33 Growth I L.P. | 4.9% | $15,408,180 | 5,002,656 | M33 Growth I L.P. | 14 May 2026 | |||
| SARIN RAVI YANG | 4.7% | $11,959,434 | 4,109,771 | Ravi Sarin | 26 Mar 2025 |
As of 30 Jun 2026, 119 institutional investors reported holding 40,090,586 shares of Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (TOI). This represents 40% of the company’s total 101,268,340 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
34%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4.7% | 4,749,030 | +7.5% | 0% | $25,787,233 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.3% | 3,360,052 | 0% | 0.19% | $18,245,082 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 3,265,531 | -6.1% | 0% | $17,731,833 |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | 2.4% | 2,464,359 | 0% | 8.4% | $13,381,469 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 1,899,998 | +8.1% | 0% | $10,319,334 |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,735,337 | +28% | 0% | $9,422,880 |
| WEXFORD CAPITAL LP | 1.7% | 1,711,323 | 0% | 1.3% | $9,292,484 |
| STATE STREET CORP | 1.5% | 1,552,917 | +6.3% | 0% | $8,432,339 |
| Nuveen, LLC | 1.4% | 1,408,720 | +1379% | 0% | $7,649,350 |
| RENAISSANCE TECHNOLOGIES LLC | 1.3% | 1,365,913 | +51% | 0.01% | $7,416,908 |
| CenterBook Partners LP | 1.2% | 1,241,660 | -21% | 0.33% | $6,742,214 |
| MARSHALL WACE, LLP | 1.2% | 1,222,498 | +257% | 0.01% | $6,638,164 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.99% | 1,007,037 | +17% | 0% | $5,468,211 |
| CITADEL ADVISORS LLC | 0.88% | 894,101 | +47% | 0% | $4,854,968 |
| JANE STREET GROUP, LLC | 0.84% | 852,163 | +101% | 0% | $4,627,245 |
| BRC Group Holdings, Inc. | 0.73% | 742,593 | -20% | 0.94% | $4,032,280 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.7% | 710,888 | +69% | 0% | $3,860,122 |
| TWO SIGMA INVESTMENTS, LP | 0.66% | 668,839 | +117% | 0% | $3,631,796 |
| NORTHERN TRUST CORP | 0.58% | 591,534 | +5.9% | 0% | $3,212,030 |
| ACADIAN ASSET MANAGEMENT LLC | 0.56% | 567,001 | 0% | $3,072,000 | |
| VANGUARD FIDUCIARY TRUST CO | 0.5% | 502,049 | +3.9% | 0% | $2,726,126 |
| FourWorld Capital Management LLC | 0.49% | 499,196 | 0% | 3.5% | $2,710,634 |
| Manatuck Hill Partners, LLC | 0.44% | 450,000 | 0.81% | $2,443,500 | |
| Walleye Capital LLC | 0.44% | 445,832 | 0.01% | $2,420,868 | |
| Inspire Investing, LLC | 0.42% | 424,008 | 0.09% | $2,302,363 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 40,090,586 | $217,590,724 | +$22,311,550 | $5.43 | 119 |
| 2026 Q1 | 38,763,593 | $118,924,902 | -$589,812 | $3.07 | 115 |
| 2025 Q4 | 38,505,676 | $137,199,596 | +$13,731,282 | $3.56 | 116 |
| 2025 Q3 | 34,670,910 | $120,993,806 | +$10,399,257 | $3.49 | 107 |
| 2025 Q2 | 31,474,503 | $64,523,702 | +$31,211,552 | $2.05 | 78 |
| 2025 Q1 | 16,901,932 | $19,267,414 | +$2,727,938 | $1.14 | 42 |
| 2024 Q4 | 14,712,600 | $4,608,917 | -$2,191,797 | $0.31 | 30 |
| 2024 Q3 | 20,589,694 | $6,982,762 | +$385,704 | $0.33 | 34 |
| 2024 Q2 | 18,701,866 | $8,832,828 | -$155,334 | $0.46 | 38 |
| 2024 Q1 | 17,222,037 | $27,535,675 | -$2,492,260 | $1.58 | 44 |
| 2023 Q4 | 18,436,129 | $37,608,749 | +$6,554,810 | $2.04 | 44 |
| 2023 Q3 | 15,107,160 | $21,169,015 | +$1,157,191 | $1.40 | 36 |
| 2023 Q2 | 13,916,345 | $7,656,692 | -$4,490,020 | $0.55 | 37 |
| 2023 Q1 | 21,905,923 | $14,849,314 | -$1,309,674 | $0.68 | 37 |
| 2022 Q4 | 23,473,725 | $38,730,078 | -$1,269,944 | $1.65 | 37 |
| 2022 Q3 | 23,327,364 | $108,006,612 | +$6,672,135 | $4.63 | 39 |
| 2022 Q2 | 21,874,386 | $110,684,000 | +$2,844,383 | $5.06 | 33 |
| 2022 Q1 | 17,791,143 | $126,852,000 | -$752,294 | $7.13 | 27 |
| 2021 Q4 | 21,118,138 | $199,883,000 | +$185,679,000 | $9.75 | 21 |
| 2021 Q3 | 252,439 | $2,504,000 | +$2,504,000 | $9.92 | 1 |